Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma

Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free survival in the adjuvant therapy setting (CHECKMATE...

Description complète

Détails bibliographiques

Auteurs principaux:	Anica Högner, Peter Thuss-Patience
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2021-02-01
Collection:	Pharmaceuticals
Sujets:	gastrointestinal cancer oesophageal cancer stomach cancer immune checkpoint inhibitors programmed death receptor nivolumab
Accès en ligne:	https://www.mdpi.com/1424-8247/14/2/151
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!